190 related articles for article (PubMed ID: 20966329)
1. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
[TBL] [Abstract][Full Text] [Related]
2. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
[TBL] [Abstract][Full Text] [Related]
4. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
Kaira K; Oriuchi N; Otani Y; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Endo K; Mori M
Chest; 2007 Apr; 131(4):1019-27. PubMed ID: 17426205
[TBL] [Abstract][Full Text] [Related]
6. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
7. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
[TBL] [Abstract][Full Text] [Related]
10. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
[TBL] [Abstract][Full Text] [Related]
11. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Ishikita T; Higuchi T; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
Cancer Sci; 2009 Apr; 100(4):753-8. PubMed ID: 19141127
[TBL] [Abstract][Full Text] [Related]
12. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study.
Kaira K; Oriuchi N; Shimizu K; Ishikita T; Higuchi T; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
Int J Cancer; 2009 Mar; 124(5):1152-60. PubMed ID: 19065657
[TBL] [Abstract][Full Text] [Related]
14. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
Jingu K; Kaneta T; Nemoto K; Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Takai Y; Takahashi S; Yamada S
Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
[TBL] [Abstract][Full Text] [Related]
15. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
[TBL] [Abstract][Full Text] [Related]
17. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
19. Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancers: a multiple-threshold method for [(18)F]fluoro-2-deoxyglucose activity.
Okubo M; Nishimura Y; Nakamatsu K; Okumura M; Shibata T; Kanamori S; Hanaoka K; Hosono M
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):350-6. PubMed ID: 20457349
[TBL] [Abstract][Full Text] [Related]
20. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]